a CBN-based topical eye drop formulation for the treatment of glaucoma; and additional discovery programs utilizing CBN and other rare cannabinoids. This growing pipeline places InMed at the ...

The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR ...

Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

Primary Open-angle, Closed-angle, Normal-tension, and Congenital are common types of glaucoma. Eye drops serve as the primary treatment, tailored to the patient’s target IOP and ocular/systemic ...

Anchor] Macular degeneration is a disease in which vision decreases due to abnormalities in the macula, the center of the ...

CHICAGO -- Upfront laser trabeculoplasty significantly slowed glaucoma progression and ... times as often when patients ...

pressure on those at risk of glaucoma. They examined 1,502 people aged between 45 and 82 who had increased intraocular pressure - placing around half on a regime of daily eye drop treatment.

Glaucoma treatments start with drops, which can prove effective for many years. If the drops start to fail then patients can move on to a trabeculectomy, which involves surgery to make a small ...

Health care and tech innovation go hand in hand. From delivering steady streams of medication to speeding up treatment of ...

The drops called Travoprost are meant to ... At Mass Eye and Ear, experts said treatment options for glaucoma have improved in recent years. “Glaucoma these days is not the same as it was ...

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A.